Background: Type 1 diabetes (T1DM) is considered to be one of the most significant risk factors for the development of coronary artery disease (CAD). However, the specific risk predictor models for T1DM are subject to many limitations.
Case Presentation: We report the case of a 42-year-old Caucasian woman presenting with T1DM for 26 years. During her chronic hyperglycemic evolution (mean of HbA1c > 3 percentage points above the superior limit) without microvascular complications, this patient presented with early and aggressive coronary artery disease, despite the lack of classical risk factors for CAD CONCLUSIONS: The rapidly progressive macrovascular disease observed in this case demonstrates the different degrees of aggressiveness and unpredictable clinical evolution observed in some cases. It also confirms the need for a multi-factorial, early and optimized clinical management regime.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681711 | PMC |
| http://dx.doi.org/10.1186/1756-0500-6-222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential cell architecture and microenvironmental responses of pretumoral and tumoral cellular models exposed to coverslip-induced hypoxia.
Histochem Cell Biol
January 2025
Departamento de Diagnóstico en Patología y Medicina Oral, Facultad de Odontología, Universidad de La República, General Las Heras 1925, Montevideo, Uruguay.
The tumor microenvironment is an altered milieu that imposes multiple selective pressures leading to the survival and dissemination of aggressive and fit tumor cell subpopulations. How pre-tumoral and tumoral cells respond to changes in their microenvironment will determine the subsequent evolution of the tumor. In this study, we have subjected pre-tumoral and tumoral cells to coverslip-induced hypoxia, which recapitulates the intracellular hypoxia and extracellular acidification characteristic of the early tumor microenvironment, and we have used a combination of quantitative phase microscopy and epifluorescence to analyze diverse cellular responses to this altered environment.
View Article and Find Full Text PDFSpatial expression of fibroblast activation protein-α in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment.
Cancer Immunol Immunother
January 2025
Biobizkaia Health Research Institute, 48903, Barakaldo, Spain.
Clear cell renal cell carcinoma (ccRCC) is one of the most challenging neoplasms because of its phenotypic variability and intratumoral heterogeneity. Because of its variability, ccRCC is a good test bench for the application of new technological approaches to unveiling its intricacies. Multiplex immunofluorescence (mIF) is an emerging method that enables the simultaneous and detailed assessment of tumor and stromal cell subpopulations in a single tissue section.
View Article and Find Full Text PDFBackground: Early detection and accurate forecasting of AD progression are crucial for timely intervention and management. This study leverages multi-modal data, including MRI scans, brain volumetrics, and clinical notes, utilizing Machine Learning (ML), Deep Learning (DL) and a range of ensemble methods to enhance the forecasting accuracy of Alzheimer's disease.
Method: We utilize the OASIS-3 longitudinal dataset, tracking 1,098 patients over 30 years.
Clinical Manifestations.
Alzheimers Dement
December 2024
Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Background: Early-onset Alzheimer's disease (EOAD) manifests prior to the age of 65. Clinical presentation of EOAD is distinct from that of late-onset Alzheimer's disease, and is characterized as having a more aggressive disease course with greater heterogeneity. Recent publications from the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) described their sample as predominantly amnestic, though this phenotypic description was based solely on clinical judgment.
View Article and Find Full Text PDFMyositis associated with pembrolizumab presenting with myastheniform symptoms: two case reports.
Anticancer Drugs
February 2025
Department of Neurology, Bezmialem Vakif University, Medical Faculty, Istanbul, Turkey.
Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have revolutionized cancer treatment by enhancing the immune system's response to malignancies. However, these therapies are associated with immune-related adverse events (irAEs), including neuromuscular complications such as myasthenia gravis, myositis, and myocarditis. We describe two male patients, aged 67 and 68, with small cell and non-small cell lung cancers, who developed progressive neuromuscular symptoms, including ptosis, diplopia, and generalized weakness, after receiving pembrolizumab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!